Paul Badawi

Paul has developed throughout his career as a Research Fellow (NIH), Welsh Fellow, and Venture Fellow (UCLA), and Kauffman Fellow (3i). He holds a BS in biological sciences from the University of Chicago and an MBA from UCLA.

Paul is an investor and entrepreneur specializing in the medical technology space. He seeks out massive unmet clinical needs that can be addressed with simple, elegant, and practical medical device solutions. Paul co-founded and serves as CEO of Sight Sciences, an innovative ophthalmic medical device company based in Menlo Park, CA. He is a co-inventor of the TRAB360 Instrument, VISCO360 System, Helix Microstent, and TearCare Dry Eye Treatment System. 

​

Prior to launching Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm. While there, he helped build a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics. 

​

Earlier in his career, Paul was Vice President of Strategy at Medrium (acquired by Nightingale); he worked as an associate at the Delta Opportunity Fund that invested in privately-held and publicly-traded biotechnology and medical device companies; and conducted and published biochemical genetics research in the laboratory of a Nobel Prize-winning biochemist at the National Heart, Lung, and Blood Institute at the NIH.

Paul is a member of Class 9 and served his fellowship at 3i under mentor Allan Ferguson.